Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors

Boris G. Naraev, Jonathan R. Strosberg, Thorvardur R. Halfdanarson

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Although neuroendocrine tumors (NET) are a relatively rare malignancy, the reported incidence is increasing, and some of the current treatment options are limited in their efficacy. Standard first-line therapy for metastatic small bowel NET includes somatostatin analogs. Although these agents can provide symptom relief and can delay disease progression in many patients, ultimately, new treatments are required for patients with progressive disease. In recent years, there has been considerable interest in developing agents specifically targeted against some of the pathways known to be involved in cancer cell growth, survival and invasion. In 2011, the mammalian target of rapamycin (mTOR) inhibitor everolimus and the tyrosine kinase inhibitor sunitinib were approved for the treatment of pancreatic NET. Clinical trials evaluating novel targeted agents are ongoing, both as single agents and in combination regimens. We review the current clinical status of these potential new treatments and highlight those with particular promise for the management of well-differentiated NET.

Original languageEnglish (US)
Pages (from-to)117-127
Number of pages11
JournalOncology (Switzerland)
Issue number3
StatePublished - Aug 2012


  • Insulin-like growth factor-1 receptor
  • Mammalian target of rapamycin
  • Neuroendocrine tumor
  • Somatostatin
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this